PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.50%
Net income growth of 12.50% while Healthcare median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
-31.48%
D&A shrinks yoy while Healthcare median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
-66.70%
Deferred tax shrinks yoy while Healthcare median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
10.78%
SBC growth of 10.78% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
-179.22%
Working capital is shrinking yoy while Healthcare median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-302.85%
AP shrinks yoy while Healthcare median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
-91.10%
Other WC usage shrinks yoy while Healthcare median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
10.78%
Growth of 10.78% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
-32.84%
Negative CFO growth while Healthcare median is 0.00%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-1.01%
CapEx declines yoy while Healthcare median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1225.23%
We reduce “other investing” yoy while Healthcare median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
-1611.06%
Reduced investing yoy while Healthcare median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
We reduce issuance yoy while Healthcare median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.